Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

CDC2-like Kinases (CLKs) Inhibition As a Novel Targeted Therapeutic Strategy in Myelodysplastic Syndromes (MDS)

Hui Yang, Zhihong Fang, Yue Wei, Juan Jose Rodriguez Sevilla, Marcos Estecio, Guillermo Montalban-Bravo, Kelly S. Chien, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 6691.

https://doi.org/10.1182/blood-2024-207573

Published: 2024

Journal Articles

Novel Therapeutic Combining CS055 with Chiglitazar Targets Leukemia Stem and Progenitor Cells in Acute Myeloid Leukemia

Hui Zhou, Dongmei Qin, Chendi Xie, Jie Zhou, Wenjuan Li, Mengya Zhong, Yuelong Jiang, Manman Deng, Haijun Zhao, Yong Zhou, Qian Lai, Zhihong Fang, Yiming Luo, Bing Xu, Jie Zha

Blood (2022) 140 (Supplement 1): 11731.

https://doi.org/10.1182/blood-2022-166807

Published: 2022

Journal Articles

Combination of CS2164 and Venetoclax Shows Synergistic Antitumor Effect in High-Grade B-Cell Lymphomas with Concomitant MYC and BCL2 Rearrangements

Manman Deng, MD PhD, Delin Yuan, MS, Genhong Li, MS, Yuelong Jiang, MS, Qinwei Chen, MD PhD, Zhihong Fang, MD PhD, Bing Xu, MD PhD

Blood (2020) 136 (Supplement 1): 41.

https://doi.org/10.1182/blood-2020-140989

Published: 2020

Journal Articles

Apatinib Exhibits Cytotoxicity to Acute Myeloid Leukemia Cell Via Targeting VEGFR2-Mediated Pro-Survival Signaling and Angiogenesis

Lian Yu, Manman Deng, Zhifeng Li, Zhihong Fang, Yun Dai, MD, Bing Xu

Blood (2019) 134 (Supplement_1): 5158.

https://doi.org/10.1182/blood-2019-123472

Published: 2019

Journal Articles

Induced PD-1 Expression on Bone Marrow CD34+ Cells from MDS Patients Treated with 5-Azacitadine in Combination with Nivolumab and/or Ipilimumab

Hui Yang, PhDMD, Zhihong Fang, Karen Clise-Dwyer, PhD, Kathryn Ruisaard, Simona Colla, PhD, Irene Ganan-Gomez, PhD, Guillermo Montalban-Bravo, MD, Kelly Soltysiak, Naval G. Daver, MD, Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2018) 132 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2018-99-119278

Published: 2018

Journal Articles

Hematologic Malignancies and Carbapenem Resistance: A Multicentre Retrospective Study from Chinese People

Bing Xu, MD PhD, Suming Huang, PhD, Lingli He, Guoshu Chen, Zhifeng Li, Pengcheng Shi, Xutao Guo, Zhihong Fang, Yan Wang, Jie Li, Yong Zhou

Blood (2017) 130 (Supplement 1): 4826.

https://doi.org/10.1182/blood.V130.Suppl_1.4826.4826

Published: 2017

Journal Articles

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Acute Myeloid Leukemia

Hui Yang, MD PhD, Zachary S. Bohannan, MA, Zhihong Fang, Irene Gañán-Gómez, PhD, Yue Wei, PhD, Linda J. Paradiso, DVM, MBA, Hiroyuki Iwamura, Dphil, Guillermo Garcia-Manero, MD

Blood (2016) 128 (22): 2756.

https://doi.org/10.1182/blood.V128.22.2756.2756

Published: 2016

Journal Articles

Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Blood (2016) 128 (22): 1640.

https://doi.org/10.1182/blood.V128.22.1640.1640

Published: 2016

Journal Articles

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Guillermo Garcia-Manero, MD, Hui Yang, MD PhD, Zhihong Fang, Courtney DiNardo, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Ricardo Delumpa, RN, Christopher Loiselle, RN, Susan Denton, RN, Whitney Smith, Hiroyuki Iwamura, PhD, Teletha Gipson, PhD, Michele Rosner, MS, Timothy Madden, PharmD, Thomas J. Myers, MD, Linda J. Paradiso, DVM, MBA

Blood (2015) 126 (23): 3800.

https://doi.org/10.1182/blood.V126.23.3800.3800

Published: 2015

Journal Articles

Association Between Downregulation of POT1 Expression and Chromosome 7 Deletion, Response to Hypomethylation Agent Treatment, and Patient Survival in Myelodysplastic Syndromes

Yue Wei, Amit Verma, MD, Monica Cabrero, MD, Yu Jia, Hong Zheng, Zhihong Fang, Yiting Yu, PhD, Simona Colla, Zach Bohannan, Teresa V. Bowman, PhD, Jacqueline Boultwood, PhD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 4663.

https://doi.org/10.1182/blood.V124.21.4663.4663

Published: 2014

Journal Articles

Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes

Yue Wei, Monica Cabrero, MD, Yu Jia, Hong Zheng, Hui Yang, MD, PhD, Zhihong Fang, Zach Bohannan, Rui Chen, PhD, Hui Wang, PhD, Simona Colla, Xia Wang, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 3241.

https://doi.org/10.1182/blood.V124.21.3241.3241

Published: 2014

Journal Articles

Expression Of Immune Checkpoints PD-L1, PD-L2, PD-1 and CTLA4 Predict For Prognosis and Resistance To Hypomethylating Agents (HMAs) In Myelodysplastic Syndromes (MDS)

Hui Yang, MD, PhD., Carlos E. Bueso-Ramos, MD, PhD, Courtney D. DiNardo, MD, Marcos R Estecio, PhD, Masoud Davanlou, MD, Qi-Rong Geng, MD, Zhihong Fang, Martin Nguyen, BS, Sherry Pierce, Yue Wei, PhD, Simrit Parmar, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2013) 122 (21): 2767.

https://doi.org/10.1182/blood.V122.21.2767.2767

Published: 2013

Journal Articles

Down-Regulated Expression Of Protection Of Telomeres 1 (POT1) Gene In Bone Marrow Hematopoietic Progenitor Cell Compartment Has Prognostic Value In Myelodysplastic Syndromes (MDS)

Yue Wei, PhD, Yu Jia, Hong Zheng, Hui Yang, M.D., Ph.D., Zhihong Fang, Simona Colla, PhD, Guillermo Garcia-Manero, MD

Blood (2013) 122 (21): 1511.

https://doi.org/10.1182/blood.V122.21.1511.1511

Published: 2013

Journal Articles

Upregulation of Focal Adhesion Kinase, a Potential Therapeutic Target, in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Hui Yang, MD, PhD., Carlos E. Bueso-Ramos, MD, PhD, Sherry A. Pierce, RN, BS, Yue Wei, PhD, Zhihong Fang, Martin Nguyen, Michael Fernadez, Marylou Cardenas-Turanzas, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 2827.

https://doi.org/10.1182/blood.V120.21.2827.2827

Published: 2012

Journal Articles

Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS)

Yue Wei, PhD, Rui Chen, Sophie Dimicoli, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, Donna S. Neuberg, ScD, Sherry A. Pierce, RN, BS, Hui Yang, MD, PhD., Yu Jia, Hong Zheng, Zhihong Fang, Martin Nguyen, Michael Fernandez, Sa A. Wang, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 1700.

https://doi.org/10.1182/blood.V120.21.1700.1700

Published: 2012

Journal Articles

Low Frequency of Molecular Alterations of H3.3-Atrx-Daxx Chromatin Remodeling Component Genes in Myelodysplastic Syndromes (MDS)

Youmna Attieh, Yue Wei, PhD, Hui Yang, MD, PhD., Yu Jia, Hong Zheng, Zhihong Fang, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3844.

https://doi.org/10.1182/blood.V120.21.3844.3844

Published: 2012

Journal Articles

Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients

Blood (2012) 120 (21): 3845.

https://doi.org/10.1182/blood.V120.21.3845.3845

Published: 2012

Journal Articles

Induction of PD-1 and PD-1 Ligand Expression by Hypomethylating Agents (HMA) in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Suggest a Role for T Cell Function in Clinical Resistance to Hmas

Hui Yang, MD, PhD., Carlos E. Bueso-Ramos, MD, PhD, Simrit Parmar, M.D., Yue Wei, PhD, Zhihong Fang, Martin Nguyen, Michael Fernandez, Sherry A. Pierce, RN, BS, Qirong Geng, Hagop M. Kantarjian, MD, Jorge E Cortes, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3810.

https://doi.org/10.1182/blood.V120.21.3810.3810

Published: 2012

Journal Articles

Toll-Like Receptor (TLR) Signaling Adaptor Protein MYD88 in Myelodysplastic Syndromes (MDS)

Sophie Dimicoli, MD, PhD, Yue Wei, PhD, Rui Chen, Carlos E. Bueso-Ramos, MD, PhD, Sherry A. Pierce, RN, BS, Hui Yang, MD, PhD., Yu Jia, Hong Zheng, Zhihong Fang, Irene ganan-Gomez, Martin Nguyen, Michael Fernandez, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 556.

https://doi.org/10.1182/blood.V120.21.556.556

Published: 2012

Journal Articles

ROS Activation Independent From Iron Overload in MDS

Francesco Paolo Tambaro, MD, PhD, William G. Wierda, MD, PhD, Sherry Pierce, RN, BS, Hui Yang, MD, PhD, Yue Wei, PhD, Zhihong Fang, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero

Blood (2011) 118 (21): 2798.

https://doi.org/10.1182/blood.V118.21.2798.2798

Published: 2011

NARROW

CDC2-like Kinases (CLKs) Inhibition As a Novel Targeted Therapeutic Strategy in Myelodysplastic Syndromes (MDS)

Novel Therapeutic Combining CS055 with Chiglitazar Targets Leukemia Stem and Progenitor Cells in Acute Myeloid Leukemia

Combination of CS2164 and Venetoclax Shows Synergistic Antitumor Effect in High-Grade B-Cell Lymphomas with Concomitant MYC and BCL2 Rearrangements

Apatinib Exhibits Cytotoxicity to Acute Myeloid Leukemia Cell Via Targeting VEGFR2-Mediated Pro-Survival Signaling and Angiogenesis

Induced PD-1 Expression on Bone Marrow CD34+ Cells from MDS Patients Treated with 5-Azacitadine in Combination with Nivolumab and/or Ipilimumab

Hematologic Malignancies and Carbapenem Resistance: A Multicentre Retrospective Study from Chinese People

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Acute Myeloid Leukemia

Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Association Between Downregulation of POT1 Expression and Chromosome 7 Deletion, Response to Hypomethylation Agent Treatment, and Patient Survival in Myelodysplastic Syndromes

Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes

Expression Of Immune Checkpoints PD-L1, PD-L2, PD-1 and CTLA4 Predict For Prognosis and Resistance To Hypomethylating Agents (HMAs) In Myelodysplastic Syndromes (MDS)

Down-Regulated Expression Of Protection Of Telomeres 1 (POT1) Gene In Bone Marrow Hematopoietic Progenitor Cell Compartment Has Prognostic Value In Myelodysplastic Syndromes (MDS)

Upregulation of Focal Adhesion Kinase, a Potential Therapeutic Target, in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS)

Low Frequency of Molecular Alterations of H3.3-Atrx-Daxx Chromatin Remodeling Component Genes in Myelodysplastic Syndromes (MDS)

Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients

Induction of PD-1 and PD-1 Ligand Expression by Hypomethylating Agents (HMA) in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Suggest a Role for T Cell Function in Clinical Resistance to Hmas

Toll-Like Receptor (TLR) Signaling Adaptor Protein MYD88 in Myelodysplastic Syndromes (MDS)

ROS Activation Independent From Iron Overload in MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only